Abstract: A method for processing iron disilicide for manufacture photovoltaic devices. The method includes providing a first sample of iron disilicide comprising at least an alpha phase entity, a beta phase entity, and an epsilon phase entity. The method includes maintaining the first sample of iron disilicide in an inert environment and subjects the first sample of iron disilicide to a thermal process to form a second sample of iron disilicide. The second sample of iron disilicide comprises substantially beta phase iron disilicide and is characterized by a first particle size. The method includes introducing an organic solvent to the second sample of iron disilicide, forming a first mixture of material comprising the second sample of iron disilicide and the organic solvent. The method processed the first mixture of material including the second sample of iron disilicide using a grinding process.

Abstract: The present invention provides for a storage stable pharmaceutical liquid solution for oral administration having a pharmaceutically effective amount of an antihistamine and having a purity equal to or greater than about 99% by weight-based HPLC assay, residual solvents of less than about 0.5%, and a total impurity of less than about 0.2%. The storage stable solution preferably contains cetirizine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid solution as well as a method of treating a mammal with a therapeutically effective amount of cetirizine in the stable pharmaceutical liquid solution.

Abstract: The disclosure is directed to a pharmaceutical kit with a first set, a second set and a third set of components. The first set of components can be a carbomer in an aqueous vehicle, the second set of components can be an antibiotic, and the third set of components can be a neutralizing agent. In exemplary embodiments, the first, second and third sets of components can be mixed together to form a spill resistant composition.

Abstract: The present invention is directed to improved liquid antibiotic formulations. In some embodiments, the present invention is directed to a composition comprising an antibiotic in a liquid comprising triglycerides, wherein the composition has less than about 5% water (w/v).

Abstract: The present invention relates to novel oral suspension formulation comprising prednisolone acetate, a pharmaceutically acceptable vehicle and a thickening agent. The present invention further provides a method of treating patients in need of prednisolone with the novel formulation.

Abstract: A coenzyme Q10 and ceramide-containing preliposome, and pharmaceutical preparations and cosmetics containing the same. The preliposome can further comprise other lipid components. A granular and lyophilized solid-preparation is produced by lyophilization or spray drying. Then, the coenzyme Q10-containing proliposome is obtained by adding water in the said solid-preparation and shaking. Transdermal absorption of coenzyme is improved together with the effect of coenzyme Q10 in cosmetics and the stability of coenzyme Q10 and liposome, which facilitate the formulation of cosmetics.

Abstract: This invention belongs to the chemical field, which is related to the fields of pharmaceutical preparations and cosmetic, especially to asiaticoside-liposome and its use for preparing pharmaceutical preparations and cosmetic. In this invention, asiaticoside and lipid components are fused by heating or dissolved in organic solvents, then treated with the rotary thin layer evaporation technique, hydrated by adding aqueous solution under shaking to afford lipid dispersing aqueous solution, and then treated by using the technics of sonication, homogeneous emulsification, microjet and extruding filtration to enwrap asiaticoside in the middle of liposomal bilayer membranes to form the hydrophilic asiaticoside-liposome.

Abstract: The present invention provides for a storage stable pharmaceutical liquid suspension for oral administration having a pharmaceutically effective amount of an antihistamine. The storage stable suspension preferably contains loratadine. The present invention further provides a process of preparing the storage stable pharmaceutical liquid suspension as well as a method of treating a mammal with a therapeutically effective amount of loratadine in the stable pharmaceutical liquid suspension.

Abstract: The invention relates to liposomal vitamin A and method of its preparing. The liposome containing vitamin A as active agent, carriers (supporter) and lipids as adjuvents and liposome-forming materials. The process comprises: adding vitamin A and lipids to carriers, forming a liposomal vitamin A in the form of solid, then rehydrating to give a liposomal dispersion. The process can improve the stability of vitamin A and liposomal vitamin A. The present liposome is useful for the manufacture of pharmaceutical and cosmetic formulation.

Abstract: The invention relates to a spill-resistant pharmaceutical composition, comprising a spill-resistant formulation with taste masking concentrations of polyethylene glycol (PEG) and diphenhydramine, which is less bitter, sweeter and has better overall flavor than current pharmaceutical compositions, while maintaining advantageous spill-resistant properties.

Abstract: A pharmaceutical suspension for oral administration, comprising a suspension of an effective amount of water insoluble active ingredient in a pharmaceutically acceptable aqueous suspension-stabilizing vehicle.

Abstract: The invention relates to a taste masking spill-resistant pharmaceutical composition, comprising a spill-resistant formulation with taste masking concentrations of polyethylene glycol (PEG) which is less bitter, sweeter and has better overall flavor than current pharmaceutical compositions, while maintaining advantageous spill-resistant properties.